Replies to post #41728 on SiNtx Technologies Inc (SINT)

[boston745]

Few years back i stumbled onto the 30 year retro study relating to the implanting of Si3N4 implants in Australia; a retro study that management at Sintx was not aware of until i posted it here. I had thought, at the time, that Centerpulse (acquired by Zimmer in 2003) had become aware of these original implants that occurred about 10 years before Sintx was born and somehow brought that tech to the US to further study through one of its surgeons Dr. Hofmann; co-founder of Sintx. After claiming this, Dr Bal corrected this statement via a conference call saying that the study in Australia was not connected to Sintx at all. He did not deny Centerpulse's involvement in Sintx early days. Nor has he ever corrected me about Zimmer Biomet's involvement in Sintx or that Zimmer sent Dr Bal to Sintx to help develop hip/knee implants in the first place. Of course those statements arent incorrect so theres nothing to deny. He even confirmed something i had been saying about large companies using small companies like Sintx to de-risk IP and then acquire it.

These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Now its possible Dr Bal confirmed this because Sintx stock was being pumped at the time, knowing i would repeatedly reference that quote, so it could acquire armor assets and then TA&T. Still, that doesnt make it untrue regardless of his motive for confirming it. So if NP Aerospace merges with Sintx that doesnt mean that this wasnt part of Zimmer Biomets's plan to see the IP derisked for licensing and then acquire it. It has spent going on 20 years working on implant development with Sintx Si3N4. As shown by a study funded by Sintx and Biomet that was released in 2007. A study that would have been conceived before 2006; Dec 2005 is when Dr Bal first joined Sintx as a surgeon designer from Zimmer. The bulk of the testing would have occurred in 2006. The initial results released at ORS in Feb 2007. It is interesting that Zimmer sent Dr Bal to Sintx to help develop a hip implant that was using Biomet's IP at the time, with Biomet helping fund the study. Less interesting now that Zimmer and Biomet have merged. A decade later Sintx and Biomet were testing Ip together again...post merger. This mean next phase comes in 2026?

2007 (ORS Annual Meeting Feb 11-14)

THERMAL CONDUCTIVITY OF FEMORAL BALL STRONGLY INFLUENCED UHMWPE WEAR IN A HIP SIMULATOR STUDY

Ten 28 mm ID isostatically moulded UHMWPE liners were investigated: GUR 1050 resin, gamma-sterilized with 25ñ40 kGy in argon (ArComô, Biomet Inc, Warsaw, IN). The liners were coupled with zirconia (Y-ZrO 2 : ProzyrÆ), cobalt-chrome (Biomet, Inc), silicon nitride (Si3 N 4 : Amedica-Inc, UT) and alumina femoral balls (Al2 O 3 : Biolox-forteÆ) (Figure 1).

Acknowledgements The authors thank Amedica, Utah, US and Biomet Inc, US for their support

2015 - Signed JDA

Quote Sources:
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
http://c.eqcdn.com/_5c7526ae538a6086a4025ef13f5136d2/amedica/db/265/660/pdf/0278.pdf

========================================


A basic roadmap laid out of Zimmer's intentions for Sintx back in 2011. This quote predates Sintx vast IP portfolio expansion. Any markets Zimmer Biomet does not currently participate in, that Sintx does, represents potential markets Zimmer Biomet can utilize Sintx to bolster its revenue through licensing as well as diversify those revenue sources.

AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

Proof Zimmer Biomet is one of Sintx strategic partners:

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017

This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Quote Sources:

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear